As previously reported, Wedbush initiated coverage of MoonLake Immunotherapeutics with an Outperform rating and $33 price target. The firm considers MoonLake Immunotherapeutics’ an opportunity to invest in a potential best-in-class IL-17A/IL-17F Nanobody to treat inflammatory diseases with high unmet needs.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MLTX:
- This Insider Just Pocketed MoonLake (NASDAQ:MLTX) Stock Worth $16.8M
- MoonLake Immunotherapeutics initiated with an Outperform at Wedbush
- MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
- MoonLake Immunotherapeutics sees cash runway into 2H24
- MoonLake Immunotherapeutics announces upcoming 2023 milestones